Vitiligo

These data indicate the necessity of further research to clarify any associations between COVID-19 infection, the virus’s associated vaccines, and progression of vitiligo.

These findings may require further evaluation using classification of age range as well as severity of disease, allowing for more precise results.

These data indicate that the early detection of vitiligo may be improved through an assessment of transplant recipients and using a multidisciplinary approach.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

This new data indicates the necessity of health providers around the world to address the mental health needs of vitiligo patients, especially among those most heavily affected.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.

Heather Woolery-Lloyd, MD, and Tarasha comment on the impact of vitiligo on a patient’s quality of life and the importance of support for patients with vitiligo.

Heather Woolery-Lloyd, MD, and Ted Lain, MD, discuss the mechanism of action and efficacy of ruxolitinib cream in the treatment of vitiligo.

Ted Lain, MD, reviews the current treatment landscape for vitiligo, highlighting topical ruxolitinib as a major advancement.

Tarasha, a patient with vitiligo, shares the treatment regimen her dermatologist recommended and the importance of patient-physician communication.

Ted Lain, MD, shares his approach to evaluating patients with a vitiligo diagnosis and the search for concomitant disease.

A patient with vitiligo talks with Heather Woolery-Lloyd, MD, about her personal journey to diagnosis and struggles with the disease.

Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.

Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.

Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.

Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.

Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.

Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.

Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.

Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.

Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.

Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.

Ted Lain, MD, reviews the rates and patterns of repigmentation of the skin in vitiligo and how the timeline is different for each patient.

Expert dermatologists share approaches to treating patients with vitiligo, focusing on patient communication and the use of combination therapy.

Heather Woolery-Lloyd, MD, comments on the emotional impact of vitiligo on patients’ quality of life.

Ted Lain, MD, breaks down the use of the Vitiligo Area Scoring Index calculations to assess vitiligo severity.

Drs Brittany Craiglow and Nada Elbuluk review the precipitating factors that trigger vitiligo, as well as segmental vs nonsegmental vitiligo.

New phase 2b findings support the oral JAK1 inhibitor's capability to improve repigmentation versus placebo.

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.